Brian Hotchkiss is the Chief Business Officer of Bexorg, a Yale University spinout building the first integrated AI and whole-human-brain platform for central nervous system drug discovery. A chemical engineer turned biotech dealmaker, he spent nearly seven years at Stealth BioTherapeutics shaping corporate strategy and helping land a transformative Alexion collaboration, then served as Chief Business Officer at Protego Biopharma before joining Bexorg. He pairs four graduate-level degrees in engineering, biology, and business with a career spent translating hard science into partnerships, capital, and commercial strategy.
Tom Smart is a biotech executive with a 25-year run of taking cancer companies from the lab bench to Wall Street and back again. He currently leads Actym Therapeutics, a cancer-immunotherapy company building bacteria-delivered gene therapies, after a career that ran through AnaptysBio, XOMA, Cell Genesys and Genetics Institute. He helped shepherd the PD-1 checkpoint inhibitor that became GSK's Jemperli, founded and sold an antifungal company, and is named in industry records as a CEO and board member at oncolytic-virus company Seneca Therapeutics. His specialty is the unglamorous middle: financings, partnerships, IPOs and acquisitions that decide whether a promising molecule ever reaches a patient.
Michael Ovitz is the most powerful talent agent in Hollywood history and co-founder of Creative Artists Agency (CAA), which he built from a $21,000 bank loan into the dominant force reshaping how entertainment deals are made. After departing with a $140 million severance from Disney's presidency, Ovitz reinvented himself as a Silicon Valley investor and advisor, backing Palantir, helping architect Andreessen Horowitz, and investing in 200+ companies. At 79, he remains a live wire: he reportedly convinced Bill Ackman to pursue a $64 billion takeover of Universal Music Group and is slated to become its chairman.